α-hederin Targets USP5 to Inhibit Colorectal Tumorigenesis by Disrupting STAT3 Deubiquitination

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Colorectal cancer (CRC) remains a significant health challenge, with its progression linked to complex molecular pathways.
• Understanding the precise mechanisms of natural compounds like α-hederin in cancer treatment is crucial for developing effective therapies.
• Signal transducer and activator of transcription 3 (STAT3) is implicated in CRC pathogenesis, but its deubiquitination regulation in this context is not fully understood.

Purpose of the Study:

• To elucidate the direct molecular targets and anti-CRC mechanism of α-hederin.
• To investigate the role of ubiquitin specific peptidase 5 (USP5) in STAT3 deubiquitination and CRC progression.
• To explore the potential of targeting the USP5-STAT3 axis for CRC treatment.

Main Methods:

• In vitro and in vivo experiments to identify direct targets of α-hederin.
• Analysis of USP5 expression and its interaction with STAT3 in CRC tissues and cell lines.
• Assessment of STAT3 deubiquitination status following α-hederin treatment.
• Evaluation of the impact of USP5 inhibition on CRC cell proliferation and tumor growth.

Main Results:

• α-hederin was identified as a direct inhibitor of USP5, a deubiquitinating enzyme (DUB).
• USP5 was found to deubiquitinate STAT3, promoting colorectal tumorigenesis and acting as an oncogene in CRC.
• α-hederin treatment decreased USP5 expression, weakened its interaction with STAT3, and inhibited STAT3 deubiquitination, thereby suppressing colorectal tumor growth.

Conclusions:

• α-hederin effectively suppresses colorectal tumorigenesis by targeting USP5 and disrupting STAT3 deubiquitination.
• USP5 is a novel STAT3 deubiquitinating enzyme and an oncogene in CRC, making it a promising therapeutic target.
• Targeting the USP5-mediated STAT3 deubiquitination pathway represents a potential new strategy for CRC treatment.